Science

Researchers create light-activated cages for 'protein killer' molecules

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 30/10/2026, 16:10:24 UTC.

Briefings

Researchers developed RuPHOTACs, a molecular cage system that renders protein-degrading drug molecules inactive until exposed to low-energy red light. This technology aims to enable targeted protein destruction while minimizing side effects. The study was published in October 2026.

Key points

• The technology is named RuPHOTACs and functions as a molecular cage that keeps drug molecules inactive until exposed to low-energy red light.
• This system allows scientists to control the timing and location of protein degradation, potentially improving the precision of treatments.

Context

This research represents a significant advancement in molecular medicine by introducing a new method for controlling protein-degrading drug molecules. It offers a potential solution for developing treatments that can destroy specific proteins while limiting unwanted effects elsewhere in the body.

Limitations

The evidence is limited to a single published article from October 2026. No further data, experimental results, or clinical trials are provided to verify the technology's effectiveness or safety.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 30/10/2026, 16:12:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihrzuz36mlnsml2qri746dr7te7fjvyfqviv4anocntswxlmdr5zy